HYDERABAD, India – Indian companies, backed by the government, are making a strong push to become world-class biosimilar manufacturers. And they might have a shot at that status if they can overcome chronic problems with quality control, limited funding and the fact that making big molecule biologics can be much more difficult than developing and manufacturing the small-molecule generics that long powered the country’s pharmaceutical industry.